ロード中...
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
OBJECTIVES: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. METHODS: We performed a multicenter, non-controlled, retrospective study of HI...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5058546/ https://ncbi.nlm.nih.gov/pubmed/27727331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0164455 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|